Abstract
The global epidemiological transition of chronic liver diseases has consolidated Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and its inflammatory form, Metabolic Dysfunction-Associated Steatohepatitis (MASH), as emerging and predominant indications for liver transplantation in the current era1. However, the resolution of end-stage liver failure by surgery exposes the recipient to a new and complex challenge: the "second metabolic hit," induced by continuous immunosuppressive therapy (especially calcineurin inhibitors and corticosteroids). This pharmacological intervention, associated with appetite recovery and improvement in prior nutritional status, triggers accelerated weight gain, development of new-onset diabetes after transplantation (NODAT), dyslipidemia, and recurrent or de novo steatosis in the allograft